USE OF SPORE OF CLOSTRIDIUM GHONII IN COMBINATION WITH PEMBROLIZUMAB
The present invention relates to the use of Clostridium ghonii in combination with pembrolizumab in cancer therapy. It is found for the first time in the present invention that Clostridium ghonii in combination with pembrolizumab can improve the efficacy thereof against colon cancer, while also reducing the dose of pembrolizumab, which is highly efficient and low toxicity. Oncolysis with Clostridium ghonii can affect the immunogenicity of TME in various ways, so that TME is changed into an immune activation state from an immunosuppression state while the immunosuppressive TME is regulated, breaking through the immunological tolerance. Approximately 20% of mouse tumor tissues are thoroughly removed by means of combining spores of Clostridium ghonii with pembrolizumab under optimal combination conditions, expanding the scope of benefits of the treatment of tumor patients with PD-1 antibodies, and also even providing efficacy for patients for which treatment with PD-1 antibodies has failed..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 29. Feb. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG YONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-02-29, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
AU2022358832 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001277197 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001277197 | ||
| 003 | DE-627 | ||
| 005 | 20240426155514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001277197 | ||
| 035 | |a (EPA)AU2022358832 | ||
| 035 | |a (EPA)79922431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG YONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a USE OF SPORE OF CLOSTRIDIUM GHONII IN COMBINATION WITH PEMBROLIZUMAB |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-02-29, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
| 520 | |a The present invention relates to the use of Clostridium ghonii in combination with pembrolizumab in cancer therapy. It is found for the first time in the present invention that Clostridium ghonii in combination with pembrolizumab can improve the efficacy thereof against colon cancer, while also reducing the dose of pembrolizumab, which is highly efficient and low toxicity. Oncolysis with Clostridium ghonii can affect the immunogenicity of TME in various ways, so that TME is changed into an immune activation state from an immunosuppression state while the immunosuppressive TME is regulated, breaking through the immunological tolerance. Approximately 20% of mouse tumor tissues are thoroughly removed by means of combining spores of Clostridium ghonii with pembrolizumab under optimal combination conditions, expanding the scope of benefits of the treatment of tumor patients with PD-1 antibodies, and also even providing efficacy for patients for which treatment with PD-1 antibodies has failed. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHU HONG |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG WENHUA |e verfasserin |4 aut | |
| 700 | 0 | |a XING YANQIU |e verfasserin |4 aut | |
| 700 | 0 | |a WANG DAN |e verfasserin |4 aut | |
| 700 | 0 | |a LIU YUANYUAN |e verfasserin |4 aut | |
| 700 | 0 | |a WANG SHAOPENG |e verfasserin |4 aut | |
| 700 | 0 | |a ZHENG JIAHUI |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG RONG |e verfasserin |4 aut | |
| 700 | 0 | |a LI XIAONAN |e verfasserin |4 aut | |
| 700 | 0 | |a XU XINGLU |e verfasserin |4 aut | |
| 700 | 0 | |a JIANG SHENGBIAO |e verfasserin |4 aut | |
| 700 | 0 | |a XING LICHAO |e verfasserin |4 aut | |
| 700 | 0 | |a GAO YUXIA |e verfasserin |4 aut | |
| 700 | 0 | |a SHAO SHILI |e verfasserin |4 aut | |
| 700 | 0 | |a HAN TING |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 29. Feb. |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/79922431/publication/AU2022358832A1?q=AU2022358832 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 02 | ||